CG Oncology, Inc. (NASDAQ:CGON) Receives $83.18 Consensus Target Price from Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been assigned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $83.1818.

Several equities research analysts have issued reports on CGON shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Truist Financial increased their price objective on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada decreased their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. upped their target price on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $74.54, for a total transaction of $74,540.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at approximately $74,540. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James Mulay sold 24,165 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the sale, the director owned 24,165 shares of the company’s stock, valued at approximately $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 38,129 shares of company stock worth $2,738,357. 4.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CGON. Jennison Associates LLC bought a new position in CG Oncology during the 4th quarter worth approximately $11,730,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in CG Oncology by 623.8% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,834 shares of the company’s stock valued at $1,571,000 after purchasing an additional 32,607 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in CG Oncology by 2.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,349,527 shares of the company’s stock valued at $56,032,000 after purchasing an additional 30,960 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of CG Oncology during the fourth quarter valued at approximately $606,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of CG Oncology during the first quarter valued at approximately $12,708,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

CG Oncology stock opened at $74.34 on Friday. The firm’s fifty day moving average price is $73.04 and its 200-day moving average price is $66.46. The stock has a market cap of $6.59 billion, a P/E ratio of -27.64 and a beta of 0.23. CG Oncology has a fifty-two week low of $26.22 and a fifty-two week high of $80.97.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%. On average, analysts predict that CG Oncology will post -3.27 earnings per share for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.